The medication works in the following ways: It binds to GLP-1 receptors to stimulate insulin secretion from pancreatic beta cells
GLP-1 receptor agonists mimic or enhance the action of glucagon-like peptide-1, an incretin hormone involved in post-meal glucose control, insulin secretion, glucagon suppression, gastric emptying, appetite, and satiety
In a clinical trial, called OASIS 4, oral semaglutide 25 mg led to an average weight loss of about 13.6 percent over 68 weeks
Nevertheless, translating these experimental technologies into safe, effective, and commercially viable products requires extensive clinical trials to establish pharmacokinetics, bioavailability, efficacy, and safety profiles
While semaglutide's delayed gastric emptying may affect the rate of absorption of some oral medicines, this is usually not clinically relevant for vitamin and mineral supplements